Details

Autor(en) / Beteiligte

• Disertori, Marcello
• Latini, Roberto
• Barlera, Simona
• Franzosi, Maria Grazia
• Staszewsky, Lidia
• Maggioni, Aldo Pietro
• Lucci, Donata
• Di Pasquale, Giuseppe
• Tognoni, Gianni

Titel

Valsartan for Prevention of Recurrent Atrial Fibrillation

Ist Teil von

• The New England journal of medicine, 2009-04, Vol.360 (16), p.1606-1617

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• In a randomized trial, 1442 patients with a history of atrial fibrillation were assigned to receive either valsartan, an angiotensin II–receptor blocker, or placebo. Antiarrhythmic therapy was administered according to the treating physician's preference. At 1 year, there was no difference between the groups in the rate of either a first recurrence or multiple recurrences of atrial fibrillation. Patients with a history of atrial fibrillation were assigned to receive either valsartan or placebo. At 1 year, there was no difference between the groups in the rate of either a first recurrence or multiple recurrences of atrial fibrillation. Atrial fibrillation is the most common cardiac arrhythmia. 1 – 5 Antiarrhythmic drugs have only moderate efficacy in preventing recurrences of atrial fibrillation and sometimes cause serious adverse reactions. 6 – 8 Ablation is a costly procedure, and accepted indications are limited. 9 , 10 Thus, new approaches to the management of atrial fibrillation continue to be the subject of interest and investigation. Some studies have shown that the recurrence of atrial fibrillation after cardioversion may be partially related to a biologic phenomenon known as remodeling, in which the electrical, mechanical, and structural properties of atrial tissue and cardiac cells are progressively and irreversibly altered, creating . . .